Abstract:De novo drug design is crucial in advancing drug discovery, which aims to generate new drugs with specific pharmacological properties. Recently, deep generative models have achieved inspiring progress in generating drug-like compounds. However, the models prioritize a single target drug generation for pharmacological intervention, neglecting the complicated inherent mechanisms of diseases, and influenced by multiple factors. Consequently, developing novel multi-target drugs that simultaneously target specific targets can enhance anti-tumor efficacy and address issues related to resistance mechanisms. To address this issue and inspired by Generative Pre-trained Transformers (GPT) models, we propose an upgraded GPT model with generative adversarial imitation learning for multi-target molecular generation called MTMol-GPT. The multi-target molecular generator employs a dual discriminator model using the Inverse Reinforcement Learning (IRL) method for a concurrently multi-target molecular generation. Extensive results show that MTMol-GPT generates various valid, novel, and effective multi-target molecules for various complex diseases, demonstrating robustness and generalization capability. In addition, molecular docking and pharmacophore mapping experiments demonstrate the drug-likeness properties and effectiveness of generated molecules potentially improve neuropsychiatric interventions. Furthermore, our model's generalizability is exemplified by a case study focusing on the multi-targeted drug design for breast cancer. As a broadly applicable solution for multiple targets, MTMol-GPT provides new insight into future directions to enhance potential complex disease therapeutics by generating high-quality multi-target molecules in drug discovery. Advancing drug discovery with the vast scale of possible structures of drug-like compounds (between 10 23 and 10 60 ) relies on Artificial Intelligence (AI). The process of generating SMILES has been accomplished by using language models like the Generative Pre-trained Transformer (GPT) model. In the meantime, regulating multiple targets to achieve the desired physiological responses is booming for treating complicated diseases. However, the recent deep generative models focus on single-target drug generation, and single-target drugs have limitations, such as requiring higher doses and causing mutations. For example, activation of Src kinase in certain breast cancer cells leads to EGFR phosphorylation and downstream effects. Consequently, designing multi-target molecules against multi-target simultaneously is highly required. Thus, we have proposed an upgraded GPT model MTMol-GPT with generative adversarial imitation learning for generating high-quality multiple targets drug-like compounds. For example, MTMol-GPT generates novel drugs targeting protein pairs such as DRD2 and HTR1A, EGFR and Src. As a broadly applicable tool, MTMol-GPT provides a rapid and accurate method for advancing drug discovery, ensuring the efficient generation of high-quality multi-target drugs.

Neural multi-task learning in drug design

MTGL-ADMET: A Novel Multi-task Graph Learning Framework for ADMET Prediction Enhanced by Status-Theory and Maximum Flow.

ADMET Property Prediction Via Multi-Task Graph Learning under Adaptive Auxiliary Task Selection

Multi-task learning models for predicting active compounds

An Overview of Multi-Task Learning in Deep Neural Networks

MLT-LE: predicting drug-target binding affinity with multi-task residual neural networks

Multi-task learning for natural language processing in the 2020s: where are we going?

Massively Multitask Networks for Drug Discovery

MTMol-GPT: De novo multi-target molecular generation with transformer-based generative adversarial imitation learning

Multi-perspective Neural Network for Dual Drug Repurposing in Alzheimer’s Disease

Artificial intelligence in multi-objective drug design

A general hypergraph learning algorithm for drug multi-task predictions in micro-to-macro biomedical networks

Multi-Task Learning in Natural Language Processing: An Overview

Pushing the Boundaries of Molecular Property Prediction for Drug Discovery with Multitask Learning BERT Enhanced by SMILES Enumeration

Evaluation Framework for AI-driven Molecular Design of Multi-target Drugs: Brain Diseases as a Case Study

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

Transformative Target-Based Approaches

MCL-DTI: Using Drug Multimodal Informationand Bi-directional Cross-Attention Learningmethod for Predicting Drug-Target Interaction

Automated design of multi-target ligands by generative deep learning

Predicting Drug-Target Interactions Binding Affinity by Using Dual Updating Multi-task Learning

KG-MTL: Knowledge Graph Enhanced Multi-Task Learning for Molecular Interaction